Baymax Research, Inc. – Trademark Portfolio

Entity Type: 03

Baymax Research, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MIMO. The owner is based in Syosset, NY.

37 Preston Lane

Syosset, NY 11791

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MIMO
MIMO
Registered 2017
BAYMAX
BAYMAX
Cancelled 2017

Trademark Classifications

Baymax Research, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Baymax Research, Inc. have?

Baymax Research, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.

What trademark classes does Baymax Research, Inc. file in?

Baymax Research, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Baymax Research, Inc.'s most well-known trademarks?

Baymax Research, Inc.'s registered trademark portfolio includes well-known marks such as MIMO. These are among 1 currently registered trademark in the portfolio.

What is Baymax Research, Inc.'s trademark registration success rate?

Baymax Research, Inc. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.